TP53 and B-cell chronic lymphocytic leukemia: Consistent with this hypothesis, we show that in CLL, where only 10–15% of tumors at diagnosis contain mutated p53 [51], stimulation of B-CLL cells by CD40L receptor, which induces the alternative NF-κB pathway, results in induction of EZH2 expression (Fig. 2).